Posted on 2/20/19
Johnson & Johnson Looks Undervalued: Time To Buy?
SummaryJohnson & Johnson is a rock-solid business.The company has an impeccable track record of cash generation and dividend payments.The baby powder controversy and competition from biosimilars . . .
Posted on 2/20/19
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Pfizer (NYSE:PFE) had big expectations for Inlyta when it launched in 2012. Over the past few years, though, it's fallen out of favor as new, more . . .
Posted on 2/20/19
Pernix Therapeutics Holdings Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
MORRISTOWN, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a holding company that owns several subsidiaries, including specialty pharmaceutical companies, today . . .
Posted on 2/20/19
Ovid Therapeutics Proposes Public Offerings of Common Stock
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people . . .
Posted on 2/19/19
Local Mother Will Be Featured In Upcoming National Cancer Campaign
Wyoming resident Darlene Robinson will be one of the 29 people featured in a new PSA in Times Square this March for Colorectal Cancer Awareness Month. . . .
Posted on 2/19/19
Covera Health Announces $8.5M Series A
Covera Health, the country’s leading provider of analytics-based programs to reduce medical misdiagnoses and improve quality of care
Posted on 2/19/19
Exicure Announces License and Development Agreement with Dermelix Biotherapeutics
SKOKIE, Ill. & NEW YORK--(BUSINESS WIRE)--Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, and Dermelix Biotherapeutics, a . . .
Posted on 2/19/19
SCWorx Announces New Customer Service Agreement
NEW YORK--(BUSINESS WIRE)--SCWorx Corp. (Nasdaq:WORX), a company that offers a SAAS based suite of data management and benchmark analytics solutions for Healthcare Providers, has expanded its . . .
Posted on 2/19/19
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today a definitive agreement with Bioblast Pharma Ltd., . . .
Posted on 2/19/19
Pfizer In NASH: Left Behind And The Desperate Refocus
SummaryPfizer is a proven pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases, as well as hematological and oncological ailments.At the end of Q4 . . .
Posted on 2/19/19
Better Buy: Celgene vs. Gilead Sciences
If there was a "Bad News Bears" team of biotechs, Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) would probably be the star players. Both Celgene and Gilead . . .
Posted on 2/19/19
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Around 20 million Americans have a progressive, life-threatening liver condition called non-alcoholic steatohepatitis (NASH), and there's isn't much doctors can do about it besides recommending fewer . . .
Posted on 2/19/19
Hoth Therapeutics Prices IPO
Hoth Therapeutics Inc., a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, . . .
Posted on 2/18/19
Outlook Therapeutics Provides Business Update
CRANBURY, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) reported financial results and business highlights for its first fiscal quarter ended December 31, . . .
Posted on 2/18/19
Tabula Rasa HealthCare Closes Offering of 1.75% Convertible Notes
MOORESTOWN, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) announced the closing of its previously announced offering of $325 million principal amount . . .
Posted on 2/18/19
Motif BioSciences Enters into Amendment Agreement with Hercules Capital
NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif . . .
Posted on 2/18/19
Hoth Therapeutics Prices IPO
NEW YORK, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc., a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications . . .
Posted on 2/15/19
Did Johnson & Johnson Just Spit in Alphabet's Face?
If you had any doubts as to whether or not Johnson & Johnson (NYSE:JNJ) is serious about robotic surgery, you now have your answer. The healthcare . . .
Posted on 2/15/19
Glenmark to Spin Off its Innovation Business into a New Company in the US
Glenmark Pharmaceuticals Ltd, a research-led integrated global pharmaceutical company, today announced that its Board of Directors has given an in-principle approval to spin off the innovation . . .
Posted on 2/14/19
Johnson & Johnson: Regulatory Headwinds Compromise Half Of Future Revenue Streams
SummaryRecently uncovered internal documents corroborate allegations of Johnson & Johnson's culpability in the development of cancer in thousands of individuals.A rule change proposal put forth by . . .
Posted on 2/14/19
PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The STRIVE Awards provide funds . . .
Posted on 2/13/19
Johnson & Johnson To Acquire Auris Health For $3.4B
Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris . . .
Posted on 2/13/19
Better Buy: Gilead Sciences vs. Pfizer
Neither Gilead Sciences (NASDAQ:GILD) nor Pfizer (NYSE:PFE) is expecting any sales growth this year. As a result, the market's already taken a swipe at both stocks, . . .
Posted on 2/12/19
Medivis Launches with $2.3M in Funding
Medivis, a medical imaging and visualization company, today officially unveiled "SurgicalAR," its augmented reality (AR) technology platform for surgical applications, at HIMSS 2019. As a Microsoft . . .
Posted on 2/12/19
Pulitzer Prize-winning Author and Notable Insurance Industry Experts Join Insurity’s Connected 2019 User Conference
HARTFORD, Conn.--(BUSINESS WIRE)--Insurity, Inc., a provider of a leading insurance platform that includes policy, billing, claims, data analytics, and digital enablement solutions, announces that Pulitzer prize-winning . . .

